MENLO PARK, Calif., March 24, 2022 (GLOBE NEWSWIRE) -- AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing treatments
SAN DIEGO--(BUSINESS WIRE)-- Primmune Therapeutics today announced interim results from its Phase 1 study in healthy volunteers with PRTX007, a novel orally-administered,
Financing co-led by seasoned healthcare investors, CAM Capital and Polaris Partners SAN DIEGO--(BUSINESS WIRE)-- Primmune Therapeutics today announced the initial closing of
FOSTER CITY, Calif., June 16, 2020 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing